» Articles » PMID: 33543710

Protective Effect of Mediterranean-type Glucose-6-phosphate Dehydrogenase Deficiency Against Malaria

Overview
Journal Elife
Specialty Biology
Date 2021 Feb 5
PMID 33543710
Citations 22
Authors
Affiliations
Soon will be listed here.
Abstract

X-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common human enzymopathy. The severe Mediterranean variant (G6PD Med) found across Europe and Asia is thought to confer protection against malaria, but its effect is unclear. We fitted a Bayesian statistical model to observed G6PD Med allele frequencies in 999 Pashtun patients presenting with acute malaria and 1408 population controls. G6PD Med was associated with reductions in symptomatic malaria incidence of 76% (95% credible interval [CI], 58-88) in hemizygous males and homozygous females combined and 55% (95% CI, 38-68) in heterozygous females. Unless there is very large population stratification within the Pashtun (confounding these results), the G6PD Med genotype confers a very large and gene-dose proportional protective effect against acute vivax malaria. The proportion of patients with vivax malaria at risk of haemolysis following 8-aminoquinoline radical cure is substantially overestimated by studies measuring G6PD deficiency prevalence in healthy subjects.

Citing Articles

Human immune system: Exploring diversity across individuals and populations.

Hoang Nguyen K, Le N, Nguyen P, Nguyen H, Hoang D, Huynh C Heliyon. 2025; 11(2):e41836.

PMID: 39911431 PMC: 11795082. DOI: 10.1016/j.heliyon.2025.e41836.


Revealing the secrets of Blue Zones.

Ulusu N Front Pharmacol. 2024; 15:1428111.

PMID: 39726786 PMC: 11669513. DOI: 10.3389/fphar.2024.1428111.


Linked-evidence modelling of qualitative G6PD testing to inform low- and intermediate-dose primaquine treatment for radical cure of Plasmodium vivax.

Gatton M PLoS Negl Trop Dis. 2024; 18(9):e0012486.

PMID: 39236082 PMC: 11407642. DOI: 10.1371/journal.pntd.0012486.


Glucose-6-phosphate Dehydrogenase Variants: Analysing in Indian Plasmodium vivax Patients.

Jakhan J, Foko L, Narang G, Singh V Acta Parasitol. 2024; 69(3):1522-1529.

PMID: 39164542 DOI: 10.1007/s11686-024-00883-2.


Implementation of Glucose-6-Phosphate Dehydrogenase (G6PD) testing for Plasmodium vivax case management, a mixed method study from Cambodia.

Cassidy-Seyoum S, Chheng K, Chanpheakdey P, Meershoek A, Hsiang M, von Seidlein L PLOS Glob Public Health. 2024; 4(7):e0003476.

PMID: 39028699 PMC: 11259306. DOI: 10.1371/journal.pgph.0003476.


References
1.
Awab G, Imwong M, Bancone G, Jeeyapant A, Day N, White N . Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial. Am J Trop Med Hyg. 2017; 97(6):1782-1787. PMC: 5805052. DOI: 10.4269/ajtmh.17-0290. View

2.
White N . Anaemia and malaria. Malar J. 2018; 17(1):371. PMC: 6194647. DOI: 10.1186/s12936-018-2509-9. View

3.
Watson J, Leopold S, Simpson J, Day N, Dondorp A, White N . Collider bias and the apparent protective effect of glucose-6-phosphate dehydrogenase deficiency on cerebral malaria. Elife. 2019; 8. PMC: 6361583. DOI: 10.7554/eLife.43154. View

4.
Luzzatto L, Arese P . Favism and Glucose-6-Phosphate Dehydrogenase Deficiency. N Engl J Med. 2018; 378(1):60-71. DOI: 10.1056/nejmra1708111. View

5.
Bienzle U, Ayeni O, LUCAS A, Luzzatto L . Glucose-6-phosphate dehydrogenase and malaria. Greater resistance of females heterozygous for enzyme deficiency and of males with non-deficient variant. Lancet. 1972; 1(7742):107-10. DOI: 10.1016/s0140-6736(72)90676-9. View